Michaela Koblížková

Dr. Michaela Koblížková

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Česká gynekologie
Verified
Journal Article
Closed access
PVPetra Vinklerová
Petra Vinklerová
LMLubos Minar
Lubos Minar
VWVit Weinberger
Vit Weinberger
MFMichal Felsinger
Michal Felsinger
MKMichaela Koblížková
Michaela Koblížková
Introduction: In the last decade, the view of endometrial cancer has shifted enormously, and the surgical approach or lymph node staging has changed significantly. We are presenting these changes with the University Hospital Brno Oncogynecology center's results in the years 2012-2021 in the actual national and European guidelines context. Methods: The retrospective unicentric observational study, national and European guidelines review. Results: In the observation period, 715 endometrial cancer patients were treated in our clinic, and 636 of them underwent surgical treatment (89%). Concerning lymph node staging, fi rstly, there is a clear trend of expanding lymphadenectomy to the paraaortic area, followed by the sentinel node bio psy introduction in the years 2018-2019, and finally, the complete transition to this method as the main staging procedure in 2021, when this examination was performed in 73% of surgeries, even with high-risk cancers limited to the uterus. Within the sentinel node bio psy expansion, a gradual decrease in laparotomy approach (maximum 41% in 2016, 18% in 2021), and blood loss (2012-2019 median 100 mL, with a decrease to 50 mL in 2020-2021) was evident. A hospitalization length stabilized at a median of 5-6 days. Conclusions: Surgical treatment of endometrial cancer has become a minimally invasive procedure for the majority of patients, the average blood loss and hospitalization length have decreased. Sentinel node bio psy has become the preferred lymph node staging method.

23 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JPJiří Presl
Jiří Presl
PHPavel Havelka
Pavel Havelka
VWVit Weinberger
Vit Weinberger
POPetra Ovesna
Petra Ovesna
PFPeter Fekete
Peter Fekete
JKJan Kostun
Jan Kostun
Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4’s role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values’ accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III–IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3–4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.

28 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MKMichaela Koblížková
Michaela Koblížková
PBPetra Bretová
Petra Bretová
LMLubos Minar
Lubos Minar
MFMichal Felsinger
Michal Felsinger
BBBranislav Babjak
Branislav Babjak
VWVit Weinberger
Vit Weinberger
Objectives: This study aimed to evaluate the introduction of sentinel lymph node biopsy (SLNB) in early-stage endometrial cancer (EC), its learning curve, and factors influencing discrepancies between surgeons and pathologists. Methods: A single-centre retrospective observational study was conducted from June 2019 to December 2024 at the Department of Obstetrics and Gynecology, University Hospital Brno and Faculty of Medicine, Masaryk University. Patients with EC with complete preoperative staging and planned for extrafascial hysterectomy with bilateral salpingo-oophorectomy and SLNB were included. Bilateral detection rates were compared among two main surgeons—one senior fellow (A) and one junior fellow (B)—and other supervised fellows. Learning curves were assessed using detection rates and cumulative sum analysis. Risk factors for failed detection were analysed. Results: In 337 patients, overall bilateral detection rates ranged from 80–92%. Surgeon A achieved 80% success by the 30th procedure and 89% at the 74th. Surgeon B, trained under A’s supervision, reached 89% but later showed a decline after operating independently. The highest concordance with pathologists was noted for Surgeon A (94.6%), followed by B (92.2%) and others (84.9%). Discrepancies were mainly associated with the presence of fibroids (p = 0.005) and adenomyosis (p = 0.018). Conclusions: SNB in EC demonstrates an optimal learning curve that can be shortened through expert guidance. Extending supervised training to 30–35 procedures reduces post-independence decline and sustains high detection rates. Bilateral success, reflecting surgeon–pathologist concordance, is a strong indicator of the quality of a Gynecologic Oncology centre.

11 September 2026 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDPavel Dundr
Pavel Dundr
JNJan Novotný
Jan Novotný
BDBen Davidson
Ben Davidson
FMFrancesca Micci
Francesca Micci
Marcin A JedrykaMarcin A Jedryka
Marcin A Jedryka
NKNikola Kudrnová
Nikola Kudrnová
High-grade endometrial stromal sarcomas (HGESS) with BCOR-alteration include sarcomas with YWHAE::NUTM2A/B fusion, ZC3H7B::BCOR fusion, BCOR -ITD, BCOR alternative fusion, and BCORL1 fusion. Recently, 4 cases of uterine sarcomas with KDM2B fusion have been described, which were suggested to belong to the category of BCOR-altered tumors. These tumors are characterized by recurrent fusions of the KDM2B gene with fusion partners including EPC1 , EP400 , and CITED1 . Morphologically, some of them may have a nonspecific spindle-cell or round-cell appearance. In other tumors, however, peculiar morphologic features combining atypical round cells with at least focal sex cord-like features and myxoid stroma were found. In our study, we described 3 additional cases of uterine sarcomas with KDM2B fusion, with fusion partners including EPC1 , EPC2 , and CREBBP . Morphologically, these tumors showed either pure spindle-cell morphology, a combination of spindle and round cells, or a heterogeneous pattern with spindle cells, round cells, and prominent hyalinization, with only focal, vague sex cord-like features. Despite possible morphologic overlap with low-grade endometrial stromal sarcomas in some cases, these tumors seem to represent a variant of HGESS belonging to the category of BCOR-altered sarcomas and have a propensity for aggressive behavior, as 2 of our patients died of disease, and the third had pelvic recurrence before being lost to follow-up.